2(S)-[2-Oxo-4(R)-propylpyrrolidin-1-yl]butyramide

Independent reference data for 2(S)-[2-Oxo-4(R)-propylpyrrolidin-1-yl]butyramide (CAS 357336-20-0), compiled from public chemistry databases.

Registry identifiers across databases

Computed descriptors

Physicochemical values on record

Documented uses on record

Used as adjunctive therapy for partial-onset seizures in patients 16 years of age or older.Brivaracetam is a relatively unique anticonvulsant that is typically used in combination with other antiepileptic medications for partial onset seizures. Brivaracetam has been linked to rare instances of serum aminotransferase and alkaline phosphatase elevations during treatment and is suspected of causing rare cases of clinically apparent drug induced liver disease.

Synonyms and trade names

Brivaracetam; 357336-20-0; Briviact; UCB 34714; UCB-34714; UCB34714; (2s)-2-[(4r)-2-oxo-4-propylpyrrolidin-1-yl]butanamide; U863JGG2IA; 1-Pyrrolidineacetamide, alpha-ethyl-2-oxo-4-propyl-, (alphaS,4R)-; CHEBI:133013; DTXSID00905081; (2S)-2-((4R)-2-Oxo-4-propylpyrrolidin-1-yl)butanamide; brivaracetamum; RefChem:57048; N03AX23; DTXCID601334183

GHS hazard classification

Reported hazard statements	H302 (66.7%), H336 (33.3%)

H302 (66.7%): Harmful if swallowed [Warning Acute toxicity, oral]

H336 (33.3%): May cause drowsiness or dizziness [Warning Specific target organ toxicity, single exposure; Narcotic effects]

What the public record says

2(S)-[2-Oxo-4(R)-propylpyrrolidin-1-yl]butyramide · CAS 357336-20-0 · C11H20N2O2. UNII U863JGG2IA. European Pharmacopoeia monograph. LogP: 1.0.

Physical description and handling notes

Source: PubChem / Wikidata; the batch COA governs where values differ.